Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT07042100

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

Led by Sun Pharma Advanced Research Company Limited · Updated on 2026-01-22

177

Participants Needed

11

Research Sites

259 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

CONDITIONS

Official Title

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willing and able to give written and dated informed consent (or legally acceptable representative/impartial witness when applicable) and available for the entire study
  • Willing and able to comply with scheduled visits, treatment plan, laboratory testing, study procedures, and restrictions, and accessible for follow-up
  • Has locally recurrent or metastatic disease (except sarcomas) which has relapsed or progressed following local standard treatment, or for which no standard treatment is available
  • Has a life expectancy of at least 3 months
Not Eligible

You will not qualify if you...

  • Any major surgery within 4 weeks before SBO-154 administration
  • Evidence of organ dysfunction or any clinically significant abnormality on physical examination
  • Known or suspected history of significant drug abuse
  • Has an uncontrolled infection needing intravenous antibiotics, antivirals, or antifungals
  • Known or suspected excessive alcohol intake in the past 12 months
  • Positive urine pregnancy test (if applicable) or positive serology tests for HIV, HCV, or HBsAg (except those with resolved Hepatitis B or C)
  • History of allergy or hypersensitivity to biological agents or drugs related to SBO-154
  • Received another investigational agent within 30 days or 5 half-lives before SBO-154 administration

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 11 locations

1

Honorhealth Research Institute

Scottsdale, Arizona, United States, 85258

Actively Recruiting

2

Sarcoma Oncology Research Center

Santa Monica, California, United States, 90403

Actively Recruiting

3

Yale University - Yale Cancer Center

New Haven, Connecticut, United States, 06510

Not Yet Recruiting

4

Hope And Healing Cancer Services, Llc

Hinsdale, Illinois, United States, 60521

Actively Recruiting

5

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

6

Scientia Clinical Research

Randwick, New South Wales, Australia, 2031

Actively Recruiting

7

Sunshine Coast University Private Hospital

Birtinya, Queensland, Australia, 4557

Actively Recruiting

8

Cancer Research South Australia

Adelaide, South Australia, Australia, 5000

Actively Recruiting

9

Tata Memorial hospital

Mumbai, Maharashtra, India, 400012

Not Yet Recruiting

10

Noble Hospital Pvt. Ltd.

Pune, Maharashtra, India, 411013

Actively Recruiting

11

All India Institute for Medical Sciences

Delhi, New Delhi, India, 110029

Actively Recruiting

Loading map...

Research Team

D

Dr. Sandeep Inamdar

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | DecenTrialz